- Tibolone
-
- $10.00 / 1kg
-
2024-04-02
- CAS:5630-53-5
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100 tons
- Tibolone
-
- $10.00 / 1kg
-
2024-03-08
- CAS:5630-53-5
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 1000kg
- Tibolone
-
- $10.00 / 1kg
-
2024-03-08
- CAS:5630-53-5
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 1000kg
|
| | Tibolone Basic information |
| | Tibolone Chemical Properties |
| Melting point | 169 °C | | Boiling point | 447.4±45.0 °C(Predicted) | | density | 1.13±0.1 g/cm3(Predicted) | | refractive index | 105 ° (C=0.54, CH2Cl2/Et2O) | | storage temp. | 2-8°C | | solubility | DMSO: soluble15mg/mL, clear | | pka | 13.10±0.60(Predicted) | | color | white to beige | | Merck | 9427 | | InChI | InChI=1/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,13,17-19,23H,5-12H2,2-3H3/t13-,17-,18+,19-,20+,21+/s3 | | InChIKey | WZDGZWOAQTVYBX-PGFZCDQENA-N | | SMILES | [C@@]12([H])[C@H](C)CC3CC(=O)CCC=3[C@@]1([H])CC[C@]1(C)[C@](CC[C@@]21[H])(O)C#C |&1:0,2,12,16,18,21,r| | | CAS DataBase Reference | 5630-53-5(CAS DataBase Reference) |
| Hazard Codes | N | | Risk Statements | 51/53 | | Safety Statements | 22-24/25-61 | | RIDADR | UN 3077 9/PG 3 | | RTECS | RC8964020 |
| | Tibolone Usage And Synthesis |
| Description | Tibolone is a synthetic steroid with weak progestational and estrogenic properties,
reportedly useful in controlling symptoms resulting from natural or surgical menopause.
It has thus far shown no significant antithrombotic effect in post-menopausal patients. | | Chemical Properties | White Solid | | Originator | Akzo (Organon) (The Netherklands) | | Uses | A synthetic steroid with weak estrogenic, androgenic and progestogenic activity. A pharamceutical used in the treatment of menopausal syndrome | | Definition | ChEBI: Estran-3-one with a double bond between positions 5 and 10, and bearing both an ethynyl group and a hydroxy group at position 17 (R-configuration). A synthetic steroid hormone drug which acts as an agonist at all five type I steroid hormon
receptors, it is used in the prevention of postmenopausal osteoporosis and for treatment of endometriosis. | | Brand name | Livial | | Pharmacokinetics | Raloxifene is rapidly absorbed following oral administration, with an estimated 60% absorption, but it has a
very low bioavailability (2%), associated with extensive phase II metabolism. The metabolites are excreted via
the bile, with potential enterohepatic recycling that could account for the interaction with cholestyramine.
Supportive of the enterohepatic recycling is the half-life of 28 hours. Metabolism of raloxifene occurs to a great
extent in the intestine and consists of glucuronide conjugation catalyzed by uridine diphosphate
glucuronosyltransferase (UGT). | | Clinical Use | Tibolone is a synthetic steroid that has been shown to increase bone mineral density similar to
alendronate. The U.S. FDA approval is pending; overseas, this agent is used for the treatment of
menopausal symptoms as well as the prevention of osteoporosis. It is considered to be a viable
alternative to conjugated equine estrogen plus micronized progesterone. | | Side effects | The most common reason for
patient withdrawal from clinical trials was vaginal bleeding (also a common side effect when estrogen
therapy is used). |
| | Tibolone Preparation Products And Raw materials |
|